Replies to post #207 on Viatris (VTRS)

[DewDiligence]

MYL launches first generic-Tecfidera in US market—pursuant to recent patent win (#msg-156376316):

https://www.prnewswire.com/news-releases/mylan-brings-critical-access-to-the-multiple-sclerosis-community-by-launching-a-more-affordable-treatment-option-through-a-first-generic-to-tecfidera-301114591.html

As a branded drug for BIIB, Tecfidera has had annualized US sales of about $3.8B.

p.s. MYL’s merger with PFE’s Upjohn segment is still on track for closing in 2020.